Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven...
Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma
About this item
Full title
Author / Creator
Yao, Yue‐Liang , Wang, Yan‐Xia , Yang, Fei‐Cheng , Wang, Chuan , Mao, Min , Gai, Qu‐Jing , He, Jiang , Qin, Yan , Yao, Xiao‐Xue , Lan, Xi , Zhu, Jiang , Lu, Hui‐Min , Zeng, Hui , Yao, Xiao‐Hong , Bian, Xiu‐Wu and Wang, Yan
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Aims
Sonic hedgehog subtype medulloblastoma is featured with overactivation of hedgehog pathway and can be targeted by SMO‐specific inhibitors. However, the resistance is frequently developed leading to treatment failure of SMO inhibitors. W535L mutation of SMO (SMOW535L) is thought to be an oncogenic driver for Sonic hedgehog subtype MB and con...
Alternative Titles
Full title
Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9160449
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9160449
Other Identifiers
ISSN
1755-5930
E-ISSN
1755-5949
DOI
10.1111/cns.13835
